Skip to main content
. 2020 Jan 3;34(1):275–282. doi: 10.21873/invivo.11771

Figure 2. Treatment outcomes. A. The overall survival (OS) stratified by the human epidermal growth factor receptor Type2 (HER2) status. B. The OS in HER2-negative patients classified by period. C. The duration of response of liver metastasis classified by HER2 status. CI: Confidence interval.

Figure 2